NEW YORK, March 21, 2019 (GLOBE NEWSWIRE) -- Attorney Advertising -- Bronstein, Gewirtz & Grossman, LLC reminds investors that a class action lawsuit has been filed against the following publicly-traded companies. You can review a copy of the Complaints by visiting the links below or you may contact Peretz Bronstein, Esq. or his Investor Relations Analyst, Yael Hurwitz of Bronstein, Gewirtz & Grossman, LLC at 212-697-6484. If you suffered a loss, you can request that the Court appoint you as lead plaintiff.  Your ability to share in any recovery doesn't require that you serve as a lead plaintiff.

Ferroglobe PLC (NASDAQ: GSM) 
Class Period: August 21, 2018 - November 26, 2018
Lead Plaintiff Deadline: March 25, 2019
For more info: www.bgandg.com/gsm

The Complaint alleges that throughout the Class Period Defendants made materially false and misleading statements and/or failed to disclose that: (1) that there was excess supply of the Company’s products; (2) that demand for the Company’s products was declining; (3) that, as a result, the pricing of the Company’s products would be materially impacted; and (4) that, as a result of the foregoing, Defendants’ positive statements about the Company’s business, operations, and prospects, were materially misleading and/or lacked a reasonable basis.

Tyme Technologies, Inc. (NASDAQ: TYME) 
Class Period: March 14, 2018 - January 18, 2019
Lead Plaintiff Deadline: March 29, 2019
For more info: www.bgandg.com/tyme

The Complaint alleges that Defendants made materially false and misleading statements and/or failed to disclose that: (1) Tyme had not adequately designed the Phase II Study to present reliable results on the efficacy of SM-88 on pancreatic cancer; (2) Tyme had failed to include an appropriate control group in its open-label Phase II clinical trial for SM-88; (3) the omission of an appropriate control group distorted the reliability of data showing the efficacy of SM-88 in the Phase II Study; and (4) as a result, Tyme’s public statements were materially false and misleading at all relevant times.

Lexicon Pharmaceuticals, Inc. (NASDAQ: LXRX) 
Class Period: March 11, 2016 - January 17, 2019
Lead Plaintiff Deadline: April 1, 2019
For more info: www.bgandg.com/lxrx.

The Complaint alleges that Defendants made materially false and misleading statements and/or failed to disclose that: (1) the data from Lexicon’s Phase 3 clinical trials assessing the safety and efficacy of Sotagliflozin in treating type 1 diabetes were not as positive as Lexicon represented; (2) the health risks posed by Sotagliflozin were severe enough to threaten its FDA approval prospects; and (3) as a result, Lexicon’s public statements were materially false and misleading at all relevant times.

Contact:
Bronstein, Gewirtz & Grossman, LLC
Peretz Bronstein or Yael Hurwitz
212-697-6484 | info@bgandg.com

Legal Disclaimer:

EIN Presswire provides this news content "as is" without warranty of any kind. We do not accept any responsibility or liability for the accuracy, content, images, videos, licenses, completeness, legality, or reliability of the information contained in this article. If you have any complaints or copyright issues related to this article, kindly contact the author above.